1. Reconciled Immunology, Rheumatology, and Dermatology Execution & Stop-Cause Profile
| Clinical Trial Metric | Verified Value | Operational Context |
|---|---|---|
| Total Phase II & III Protocols (2018 to 2026) | 3,376 | Deterministic primary MeSH and condition-keyword assignment |
| Active Concurrent Pipeline | 1,326 | Recruiting, enrolling by invitation, and active follow-up protocols |
| Completed vs Prematurely Stopped | 1,249 / 466 | 27.17% closed-trial attrition ratio across 1,715 closed protocols |
| Slow Accrual vs Safety & Futility Stops | 65 / 70 / 45 | Slow accrual (WS1) vs clinical safety (WS4) vs interim futility (WS5) |
| Physical Hospital Site Disclosure Rate | 78.5% | Named hospital campus participations vs anonymized CRO site slots |
2. Leading Consolidated Trial Sponsors Focused on Immunology, Rheumatology, and Dermatology
| Sponsor Hub | Sector | Protocols | Active | Completed | FDA NDA/BLA |
|---|---|---|---|---|---|
| AbbVie | Biopharma Industry | 324 | 128 | 150 | 189 |
| Amgen | Biopharma Industry | 153 | 66 | 56 | 44 |
| Incyte | Biopharma Industry | 119 | 38 | 47 | 6 |
| UCB | Biopharma Industry | 86 | 22 | 49 | 30 |
| Keymed Biosciences Co | Biopharma Industry | 49 | 23 | 17 | 0 |
| Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Academic / Institutional Sponsor | 46 | 4 | 19 | 0 |
| Sunshine Guojian Pharmaceutical (Shanghai) Co | Biopharma Industry | 39 | 14 | 10 | 0 |
| LEO Pharma | Biopharma Industry | 33 | 5 | 25 | 0 |
| Guangdong Hengrui Pharmaceutical Co | Biopharma Industry | 32 | 24 | 7 | 0 |
| Charite University, Berlin, Germany | Academic / Institutional Sponsor | 28 | 9 | 6 | 0 |
| Viatris | Biopharma Industry | 24 | 8 | 14 | 61 |
| Celltrion | Biopharma Industry | 23 | 5 | 16 | 12 |
3. Representative Multi-Center Phase II & III Immunology, Rheumatology, and Dermatology Studies
| NCT Study | Protocol Brief Title | Sponsor | Phase | Status |
|---|---|---|---|---|
| NCT07453004 | A Study to Evaluate the Efficacy,Safety,Tolerability,Pharmacokinetics,and Immunogenicty of Plonmarlimab in Subjects With Acute Gouty Arthritis | TJ Biopharma Co | Phase II | RECRUITING |
| NCT07378527 | Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria | Beijing InnoCare Pharma Tech Co | Phase II/III | RECRUITING |
| NCT07515014 | A Study of E6742 in Participants With Systemic Lupus Erythematosus | Eisai | Phase II | RECRUITING |
| NCT07184944 | A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease | Sanofi | Phase III | RECRUITING |
| NCT07265570 | Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA) | InSilico Medicine Hong Kong Limited | Phase II | RECRUITING |
| NCT06842199 | Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis | Beijing InnoCare Pharma Tech Co | Phase III | RECRUITING |
| NCT07440537 | Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study | Beijing InnoCare Pharma Tech Co | Phase II | RECRUITING |
| NCT07185009 | A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis | Sanofi | Phase III | RECRUITING |
| NCT07047612 | ICP-332 in Subjects With Non-segmental Vitiligo | Beijing InnoCare Pharma Tech Co | Phase II/III | RECRUITING |
| NCT06300320 | A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease | Chia Tai Tianqing Pharmaceutical Group Co | Phase II | RECRUITING |
| NCT06454357 | A Clinical Study of B007 in the Treatment of Pemphigus. | Shanghai Jiaolian Drug Research and Development Co | Phase II/III | RECRUITING |
| NCT06775860 | ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis | Beijing InnoCare Pharma Tech Co | Phase III | RECRUITING |
| NCT07038382 | A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis | Shanghai Henlius Biotech | Phase II | RECRUITING |
| NCT07724366 | A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co | Phase III | RECRUITING |
| NCT07184996 | An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis | Sanofi | Phase III | RECRUITING |
| NCT07184931 | An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease | Sanofi | Phase III | RECRUITING |
Related Therapeutic Condition Hubs & Crosswalks
Compare adjacent clinical cohorts: Oncology and Hematology · Rare Genetic, Women's Health, and Other · Infectious Disease and Vaccines · Neurology, Psychiatry, and Pain, browse the interactive Hospital & Sponsor Directory, or read the Healthcare Price & Patent Cliff Crosswalk.